Significance of the progesterone receptor and epidermal growth factor receptor, but not the estrogen receptor, in chemically induced lung carcinogenesis in female A/J mice

Kishi,Sosuke; Yokohira,Masanao; Yamakawa,Keiko; Saoo,Kousuke; Imaida,Katsumi

doi:10.3892/ol.2014.2559

Significance of the progesterone receptor and epidermal growth factor receptor, but not the estrogen receptor, in chemically induced lung carcinogenesis in female A/J mice

Authors:
- Sosuke Kishi
- Masanao Yokohira
- Keiko Yamakawa
- Kousuke Saoo
- Katsumi Imaida
View Affiliations

Affiliations: Department of Pathology and Host‑Defense, Faculty of Medicine, Kagawa University, Kagawa 761‑0793, Japan
Published online on: September 24, 2014 https://doi.org/10.3892/ol.2014.2559
Pages: 2379-2386

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

In the present study, the expression levels of female hormone receptors, estrogen receptor (ER) and progesterone receptor (PR) and the epidermal growth factor receptor, (EGFR), as well as proliferating cell nuclear antigen (PCNA) were examined in lung tumors that were induced by 4‑(methylnitrosamino)‑1‑(3‑pyridyl)‑1‑butanone (NNK) in female A/J mice. Each seven‑week‑old mouse was administered with 2 mg NNK via intraperitoneal injection and the mice were subsequently euthanized at week 52. Lung tumors, including adenomas, carcinomas in adenomas and adenocarcinomas, were obtained and analyzed by immunohistochemistry for the expression levels of the receptors, ER, PR and EGFR, and PCNA. The results were as follows: i) In mouse lung adenomas, a significant correlation was identified between the size of the tumor and PCNA expression, although not with the expression of the receptors (ER, PR and EGFR); ii) in the carcinoma components of the carcinomas in adenomas, the size of the tumor and PCNA expression were correlated, while EGFR expression demonstrated a significant correlation with PR expression; iii) in adenocarcinomas, the tumor size significantly correlated with PCNA, EGFR and PR expression; and iv) EGFR and PR expression was identified to be significantly correlated in adenocarcinomas, and to a certain extent in the carcinoma components of the carcinomas in adenomas, although not in the adenomas. Notably, ER expression was not associated with tumor growth or the other factors, particularly EGFR expression, and no significant differences were identified between the three types of lesion. These results indicate that PR, like EGFR, may be significant in lung carcinogenesis.

View Figures

View References

1	Ferlay J, Shin HR, Bray F, et al: Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. Int J Cancer. 127:2893–2917. 2010.
2	Jemal A, Murray T, Ward E, et al: Cancer statistics, 2005. CA Cancer J Clin. 55:10–30. 2005.
3	Patel JD, Bach PB and Kris MG: Lung cancer in US women: a contempory epidemic. JAMA. 291:1763–1768. 2004.
4	Jemal A, Ward E and Thun M: Declining death rates reflect progress against cancer. PLoS One. 5:e95842010.
5	Subramanian J and Govindan R: Lung cancer in never smokers: a review. J Clin Oncol. 25:561–570. 2007.
6	Stabile LP, Davis AL, Gubish CT, et al: Human non-small cell lung tumors and cells derived from normal lung express both estrogen receptor alpha and beta and show biological responses to estrogen. Cancer Res. 62:2141–2150. 2002.
7	Niikawa H, Suzuki T, Miki Y, et al: Intratumoral estrogens and estrogen receptors in human non-small cell lung carcinoma. Clin Cancer Res. 14:4417–4426. 2008.
8	Taioli E and Wynder EL: Re: Endocrine factors and adenocarcinoma of the lung in women. J Natl Cancer Inst. 86:869–870. 1994.
9	Ganti AK, Sahmoun AE, Panwalkar AW, Tendulkar KK and Potti A: Hormone replacement therapy is associated with decreased survival in women with lung cancer. J Clin Oncol. 24:59–63. 2006.
10	Weinberg OK, Marquez-Garban DC, Fishbein MC, et al: Aromatase inhibitors in human lung cancer therapy. Cancer Res. 65:11287–11291. 2005.
11	Pietras RJ, Márquez DC, Chen HW, et al: Estrogen and growth factor receptor interactions in human breast and non-small cell lung cancer cells. Steroids. 70:372–381. 2005.
12	Pietras RJ and Márquez-Garbán DC: Membrane-associated estrogen receptor signaling pathways in human cancers. Clin Cancer Res. 13:4672–4676. 2007.
13	Gruber CJ, Tschugguel W, Schneeberger C and Huber JC: Production and actions of estrogens. N Engl J Med. 346:340–352. 2002.
14	Massaro D, Clerch LB and Massaro GD: Estrogen receptor-alpha regulates pulmonary alveolar loss and regeneration in female mice: morphometric and gene expression studies. Am J Physiol Lung Cell Mol Physiol. 293:L222–L228. 2007.
15	Morani A, Warner M and Gustafsson JA: Biological functions and clinical implications of oestrogen receptors alfa and beta in epithelial tissues. J Intern Med. 264:128–142. 2008.
16	Check JH, Sansoucie L, Chern J and Dix E: Mifepristone treatment improves length and quality of survival of mice with spontaneous lung cancer. Anticancer Res. 30:119–122. 2010.
17	Raso MG, Behrens C, Herynk MH, et al: Immunohistochemical expression of estrogen and progesterone receptors identifies a subset of NSCLCs and correlates with EGFR mutation. Clin Cancer Res. 15:5359–5368. 2009.
18	Su J-M, Hsu HK, Chang H, et al: Expression of estrogen and progesterone receptors in non-small-cell lung cancer: immunohistochemical study. Anticancer Res. 16:3803–3806. 1996.
19	Stabile LP, Dacic S, Land SR, et al: Combined analysis of estrogen receptor beta-1 and progesterone receptor expression identifies lung cancer patients with poor outcome. Clin Cancer Res. 17:154–164. 2011.
20	Skov BG, Fischer BM and Pappot H: Oestrogen receptor beta over expression in males with non-small cell lung cancer is associated with better survival. Lung Cancer. 59:88–94. 2008.
21	Di Nunno L, Larsson LG, Rinehart JJ and Beissner RS: Estrogen and progesterone receptors in non-small cell lung cancer in 248 consecutive patients who underwent surgical resection. Arch Pathol Lab Med. 124:1467–1470. 2000.
22	Lynch TJ, Bell DW, Sordella R, et al: Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N Engl J Med. 350:2129–2139. 2004.
23	Pao W, Miller V, Zakowski M, et al: EGF receptor gene mutations are common in lung cancers from ‘never smokers’ and are associated with sensitivity of tumors to gefitinib and erlotinib. Proc Natl Acad Sci USA. 101:13306–13311. 2004.
24	Paez JG, Jänne PA, Lee JC, et al: EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy. Science. 304:1497–1500. 2004.
25	Giaccone G: Epidermal growth factor receptor inhibitors in the treatment of non-small-cell lung cancer. J Clin Oncol. 23:3235–3242. 2005.
26	Han SW, Kim TY, Hwang PG, et al: Predictive and prognostic impact of epidermal growth factor receptor mutation in non-small-cell lung cancer patients treated with gefitinib. J Clin Oncol. 23:2493–2501. 2005.
27	Shigematsu H, Lin L, Takahashi T, et al: Clinical and biological features associated with epidermal growth factor receptor gene mutations in lung cancers. J Natl Cancer Inst. 97:339–346. 2005.
28	Mitsudomi T, Kosaka T, Endoh H, et al: Mutations of the epidermal growth factor receptor gene predict prolonged survival after gefitinib treatment in patients with non-small-cell lung cancer with postoperative recurrence. J Clin Oncol. 23:2513–2520. 2005.
29	Jänne PA, Engelman JA and Johnson BE: Epidermal growth factor receptor mutations in non-small-cell lung cancer: implications for treatment and tumor biology. J Clin Oncol. 23:3227–3234. 2005.
30	Pao W and Miller VA: Epidermal growth factor receptor mutations, small-molecule kinase inhibitors, and non-small-cell lung cancer: current knowledge and future directions. J Clin Oncol. 23:2556–2568. 2005.
31	Imaida K, Yokohira M and Kuno T: Detection of carcinogenic and modifying potentials by test compounds using a mouse lung carcinogenesis bioassay. J Toxicol Pathol. 20:117–123. 2007.
32	Yamakawa K, Kuno T, Hashimoto N, et al: Molecular analysis of carcinogen-induced rodent lung tumors: Involvement of microRNA expression and Kras or Egfr mutations. Mol Med Rep. 3:141–147. 2010.
33	Takeuchi H, Saoo K, Matsuda Y, et al: 8-Methoxypsoralen, a potent human CYP2A6 inhibitor, inhibits lung adenocarcinoma development induced by 4-(methylnitrosamino) -1-(3-pyridyl)-1-butanone in female A/J mice. Mol Med Rep. 2:585–588. 2009.
34	Renne R, Brix A, Harkema J, et al: Proliferative and nonproliferative lesions of the rat and mouse respiratory tract. Toxicol pathol. 37:5S–73S. 2009.
35	[No authors listed]. The Coronary Drug Project. Findings leading to discontinuation of the 25-mg day estrogen group. JAMA. 226:652–657. 1973.
36	Chlebowski RT, Schwartz AG, Wakelee H, et al: Women’s Health Initiative Investigators: Oestrogen plus progestin and lung cancer in postmenopausal women (Women’s Health Initiative trial): a post-hoc analysis of a randomised controlled trial. Lancet. 374:1243–1251. 2009.
37	Slatore CG, Chien JW, Au DH, Satia JA and White E: Lung cancer and hormone replacement therapy: association in the vitamins and lifestyle study. J Clin Oncol. 28:1540–1546. 2010.
38	Chlebowski RT, Anderson GL, Manson JE, et al: Lung cancer among postmenopausal women treated with estrogen alone in the women’s health initiative randomized trial. J Natl Cancer Inst. 102:1413–1421. 2010.
39	Kitahashi T, Takahashi M, Yamada Y, et al: Occurrence of mutations in the epidermal growth factor receptor gene in X-ray-induced rat lung tumors. Cancer Sci. 99:241–245. 2008.
40	Gealy R, Zhang L, Siegfried JM, Luketich JD and Keohavong P: Comparison of mutations in the p53 and K-ras genes in lung carcinomas from smoking and nonsmoking women. Cancer Epidemiol Biomarkers Prev. 8:297–302. 1999.
41	Hainaut P and Pfeifer GP: Patterns of p53 G → T transversions in lung cancers reflect the primary mutagenic signature of DNA-damage by tobacco smoke. Carcinogenesis. 22:367–374. 2001.
42	Zerbe LK, Dwyer-Nield LD, Fritz JM, et al: Inhibition by erlotinib of primary lung adenocarcinoma at an early stage in male mice. Cancer Chemother Pharmacol. 62:605–620. 2008.